Mission
AERASYN Biotech
Engineering the next generation of psychedelic-derived neurotherapeutics.
AERASYN integrates molecular design, proprietary synthesis, precision formulation, advanced delivery and translational development to build differentiated therapeutics around established psychedelic pharmacology.
Lead preclinical programs: Buccal Ibogaine and Buccal 5-MeO-DMT.
AERASYN Biotech
What is AERASYN Biotech?
AERASYN is a biotechnology company developing psychedelic-derived neurotherapeutics, led by Buccal Ibogaine and Buccal 5-MeO-DMT.
The company combines molecular design, proprietary synthesis, precision formulation, delivery and translational development across a broader intellectual-property portfolio—building a scientific platform designed for scalable therapeutic development.
2 Lead Programs23+ Patents FiledIntegrated Development Platform
Vision
Become the platform partner behind the next generation of psychedelic medicines.
Our pipeline
Four programs across differentiated molecules and delivery approaches.
AERASYN is advancing psychedelic-derived neurotherapeutic programs spanning buccal delivery, modified molecular profiles and oral formulation research.
Buccal Ibogaine
Formulation + buccal delivery
Buccal 5-MeO-DMT
Formulation + buccal delivery
PEGylated Synthetic Psilocin Analogs
Modified molecular-profile exploration
Oral Bufotenin
Oral formulation exploration